Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 8/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23123303 | 0.89 | CHRM1 (0.44) | CHRM1NAAAGAAEPHX1EPHX2 | |
| SCHEMBL23123302 | 0.89 | CHRM1 (0.44) | CHRM1NAAAGAAEPHX1EPHX2 | |
| Hydrochloric Acid SCHEMBL23123833 | 0.86 | CHRM1 (0.39) | CHRM1CHRM2CHRM3PREPNAAA | |
| SCHEMBL24700254 | 0.82 | CHRM1 (0.64) | CHRM1CHRM2CHRM3PREPMEN1 | |
| SCHEMBL28564603 | 0.81 | CHRM1 (0.66) | CHRM1CHRM2CHRM3PREPCHRM5 | |
| SCHEMBL28564604 | 0.81 | CHRM1 (0.66) | CHRM1CHRM2CHRM3PREPCHRM5 | |
| SCHEMBL21739046 | 0.81 | CHRM1 (0.66) | CHRM1CHRM2CHRM3PREPCHRM5 | |
| SCHEMBL29795100 | 0.77 | CHRM1 (0.39) | CHRM1CHRM2CHRM3PREPNAAA | |
| SCHEMBL24700461 | 0.77 | CHRM1 (0.42) | CHRM1NAAAGAAEPHX1EPHX2 | |
| Hydrochloric Acid SCHEMBL23123841 | 0.76 | CHRM1 (0.41) | CHRM1NAAAGAAEPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| EP-4031540-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021055630-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL- BIOTECH INVESTMENTS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | CHRM1 4097/4885CHRM2 3991/4885CHRM3 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.